License allows the Company to commence large-scale extraction of castanospermine from the seeds of Castanospermum australe Company will meet with FDA on July 1, 2026, to discuss Non-Notified Letter...
Enrollment is tracking ahead of schedule, allowing potential acceleration of key trial milestones Minimum enrollment to support interim analysis expected as soon as early July 2026 Randomized, double-blind,...
WASHINGTON, May 15, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP ; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for infectious...
Travelers can now purchase the only once-weekly, broad-spectrum malaria preventive online, through the Runway Health telehealth platform WASHINGTON, April 15, 2026 (GLOBE NEWSWIRE) -- 60 Degrees...
FY 2025 net product revenues increased 65% to $1,005,000 Current shelf capacity exhausted after raise of $4 million through an ATM facility WASHINGTON, March 31, 2026 (GLOBE NEWSWIRE) -- 60 Degrees...
FDA has until May 25, 2026 to object to the notification, after which the Company will be free to market its proposed dietary supplement containing Australian Chestnut Extract Company has signed an option...
All three patients enrolled in study have been cured, confirming high cure rate of tafenoquine in immunosuppressed patients, as reported by Yale in a 2024 publication Company calls for existing babesiosis...
GoodRx to offer prescription savings of up to 30% for ARAKODA ® ( tafenoquine ) Collaboration designed to lower patient out-of-pocket costs and expand the reach of Company’s marketing strategy Partnership...
WASHINGTON, Jan. 28, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees Pharma” or the “Company”), a pharmaceutical company focused on developing...
Partnership adds a travel-focused consumer telehealth platform to the ARAKODA ® marketing strategy, offering a new convenience to people planning travel to malaria-endemic regions of the world ARAKODA...